Maintenance therapy and drug holiday in sarcoma patients: systematic review

被引：10

作者：

Lebellec, Loic ^{[1
,2
]}

Defachelles, Anne-Sophie ^{[3
]}

Cren, Pierre-Yves ^{[2
]}

Penel, Nicolas ^{[2
,4
]}

机构：

[1] Gustave Dron Hosp Tourcoing, Med Oncol Unit, Tourcoing, France

[2] Lille Univ, Med Sch, Lille, France

[3] Ctr Oscar Lambret, Pediat & Adolescents Young Adults Oncol Unit, Lille, France

[4] Ctr Oscar Lambret, Med Oncol Dept, 3 Rue Frederic Combemale, F-59000 Lille, France

来源：

ACTA ONCOLOGICA | 2020年 / 59卷 / 09期

关键词：

SOFT-TISSUE SARCOMA; RAPAMYCIN INHIBITOR RIDAFOROLIMUS; HIGH-GRADE OSTEOSARCOMA; RANDOMIZED PHASE-III; MURAMYL TRIPEPTIDE; OPEN-LABEL; MAMMALIAN TARGET; T-DIS; DOXORUBICIN; CHEMOTHERAPY;

D O I：

10.1080/0284186X.2020.1759825

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Overall prognosis of advanced sarcoma remains poor, optimization of systemic treatment is urgently needed in this setting. Materials and methods: We systematically reviewed fully published English-speaking literature about maintenance therapy and drug holiday in sarcoma patients management. Results: We found that switch maintenance therapy with cyclophosphamide/vinorelbine improves the outcome of localized high-risk rhabdomyosarcoma. There is no other maintenance therapy recommended in sarcoma patients. After classical chemotherapy, maintenance therapy with immune-stimulating agents for localized osteosarcoma, bevacizumab for advanced angiosarcoma or pediatric advanced sarcoma, or mTOR inhibitors for metastatic sarcoma does not improve the outcome. Drug holiday has been assessed for metastatic gastrointestinal stromal tumor treated with imatinib as the first-line therapy or for metastatic soft-tissue sarcoma treated with trabectedin. Drug holiday has been found to lead to rapid disease progression and should be avoided. Conclusions: Data about both maintenance and drug holiday are spare in sarcoma management.

引用

页码：1084 / 1090

页数：7

共 27 条

[1] An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas† [J].

Agulnik, M. ;

Yarber, J. L. ;

Okuno, S. H. ;

von Mehren, M. ;

Jovanovic, B. D. ;

Brockstein, B. E. ;

Evens, A. M. ;

Benjamin, R. S. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :257-263

[2] Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial [J].

Bielack, Stefan S. ;

Smeland, Sigbjorn ;

Whelan, Jeremy S. ;

Marina, Neyssa ;

Jovic, Gordana ;

Hook, Jane M. ;

Krailo, Mark D. ;

Gebhardt, Mark ;

Papai, Zsuzsanna ;

Meyer, James ;

Nadel, Helen ;

Randall, R. Lor ;

Deffenbaugh, Claudia ;

Nagarajan, Rajaram ;

Brennan, Bernadette ;

Letson, G. Douglas ;

Teot, Lisa A. ;

Goorin, Allen ;

Baumhoer, Daniel ;

Kager, Leo ;

Werner, Mathias ;

Lau, Ching C. ;

Hall, Kirsten Sundby ;

Gelderblom, Hans ;

Meyers, Paul ;

Gorlick, Richard ;

Windhager, Reinhard ;

Helmke, Knut ;

Eriksson, Mikael ;

Hoogerbrugge, Peter M. ;

Schomberg, Paula ;

Tunn, Per-Ulf ;

Kuehne, Thomas ;

Juergens, Heribert ;

van den Berg, Henk ;

Bohling, Tom ;

Picton, Susan ;

Renard, Marleen ;

Reichardt, Peter ;

Gerss, Joachim ;

Butterfass-Bahloul, Trude ;

Morris, Carol ;

Hogendoorn, Pancras C. W. ;

Seddon, Beatrice ;

Calaminus, Gabriele ;

Michelagnoli, Maria ;

Dhooge, Catharina ;

Sydes, Matthew R. ;

Bernstein, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (20) :2279-U92

[3] Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial [J].

Bisogno, Gianni ;

De Salvo, Gian Luca ;

Bergeron, Christophe ;

Gallego Melcon, Soledad ;

Merks, Johannes H. ;

Kelsey, Anna ;

Martelli, Helene ;

Minard-Colin, Veronique ;

Orbach, Daniel ;

Glosli, Heidi ;

Chisholm, Julia ;

Casanova, Michela ;

Zanetti, Ilaria ;

Devalck, Christine ;

Ben-Arush, Myriam ;

Mudry, Peter ;

Ferman, Sima ;

Jenney, Meriel ;

Ferrari, Andrea .

LANCET ONCOLOGY, 2019, 20 (11) :1566-1575

[4]

Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183

[5] Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas - Pilot study for the upcoming European rhabdomyosarcoma protocol [J].

Casanova, M ;

Ferrari, A ;

Bisogno, G ;

Merks, JHM ;

De Salvo, GL ;

Meazza, C ;

Tettoni, K ;

Provenzi, M ;

Mazzarino, I ;

Carli, M .

CANCER, 2004, 101 (07) :1664-1671

[6] Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas [J].

Chawla, Sant P. ;

Staddon, Arthur P. ;

Baker, Laurence H. ;

Schuetze, Scott M. ;

Tolcher, Anthony W. ;

D'Amato, Gina Z. ;

Blay, Jean-Yves ;

Mita, Monica M. ;

Sankhala, Kamalesh K. ;

Berk, Lori ;

Rivera, Victor M. ;

Clackson, Tim ;

Loewy, John W. ;

Haluska, Frank G. ;

Demetri, George D. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (01) :78-84

[7] Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study) [J].

Chisholm, Julia C. ;

Merks, Johannes H. M. ;

Casanova, Michela ;

Bisogno, Gianni ;

Orbach, Daniel ;

Gentet, Jean-Claude ;

Thomassin-Defachelles, Anne-Sophie ;

Chastagner, Pascal ;

Lowis, Stephen ;

Ronghe, Milind ;

McHugh, Kieran ;

van Rijn, Rick R. ;

Hilton, Magalie ;

Bachir, Jeanette ;

Furst-Recktenwald, Sabine ;

Geoerger, Birgit ;

Oberlin, Odile .

EUROPEAN JOURNAL OF CANCER, 2017, 83 :177-184

[8] Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas [J].

D'Adamo, DR ;

Anderson, SE ;

Albritton, K ;

Yamada, J ;

Riedel, E ;

Scheu, K ;

Schwartz, GK ;

Chen, H ;

Maki, RG .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7135-7142

[9] Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy [J].

Demetri, George D. ;

Chawla, Sant P. ;

Ray-Coquard, Isabelle ;

Le Cesne, Axel ;

Staddon, Arthur P. ;

Milhem, Mohammed M. ;

Penel, Nicolas ;

Riedel, Richard F. ;

Binh Bui-Nguyen ;

Cranmer, Lee D. ;

Reichardt, Peter ;

Bompas, Emmanuelle ;

Alcindor, Thierry ;

Rushing, Daniel ;

Song, Yang ;

Lee, Ruey-min ;

Ebbinghaus, Scot ;

Eid, Joseph E. ;

Loewy, John W. ;

Haluska, Frank G. ;

Dodion, Pierre F. ;

Blay, Jean-Yves .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) :2485-+

[10] VINCA ALKALOIDS - ANTIVASCULAR EFFECTS IN A MURINE TUMOR [J].

HILL, SA ;

LONERGAN, SJ ;

DENEKAMP, J ;

CHAPLIN, DJ .

EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) :1320-1324

← 1 2 3 →